Kyle B. Brothers, MD, PhD and Esther E. Knapp, MD, MBE
Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.
AMA J Ethics. 2018;20(9):E812-818. doi:
10.1001/amajethics.2018.812.
Dr Matthew C. Bobel joins Ethics Talk to discuss his article, coauthored with Dr Robert K. Cleary: “How Should Risk Be Communicated to Patients When Developing Resident Surgeon Robotic Skills?”
Chromosomal microarray analysis reveals many gene variants of unknown significance. The uncertainty about these variants—might they be deleterious or are they benign?—complicates genetic counseling.
The physician must consider the potential benefits of the new procedure and then determine, through discussion with the patient, what value the patient places on those specific benefits.
Ruth M. Farrell, MD, MA, Holly Pederson, MD, and Shilpa Padia, MD
Though they claim to, direct-to-consumer genetic tests may not correctly identify an individual's ancestral background, and thus may overstate or understate one's risk for heritable disease.
Allan B. Peetz, MD, Nicholas Sadovnikoff, MD, and Michael F. O’Connor, MD
Because of their serious medical conditions and the nature of the treatments, patients who are candidates for extracorporeal life support may not be able to give properly informed consent for the treatment.
AMA J Ethics. 2015;17(3):236-242. doi:
10.1001/journalofethics.2015.17.3.stas1-1503
J. Brian Szender, MD, MS and Shashikant B. Lele, MD
The estimated reduction in risk of ovarian cancer for any woman undergoing opportunistic removal of the Fallopian tubes is up to 50 percent, but whether removal is more beneficial than ligation has not been established.
AMA J Ethics. 2015;17(9):843-848. doi:
10.1001/journalofethics.2015.17.9.stas1-1509.